GLP-1 therapy: what to know before you start

GLP-1 medications have changed weight management for millions of people. Semaglutide, tirzepatide, and the next generation of GLP-1 receptor agonists produce results that diet and exercise alone rarely match for patients with obesity or metabolic disease. They also produce real questions — about cost, safety, who they’re actually for, and how to use them as part of a sustainable program rather than a quick fix.

If you’re considering GLP-1 therapy in 2026, here’s what’s worth knowing before you start.

How GLP-1 medications work

GLP-1 (glucagon-like peptide-1) is a hormone your body produces naturally in response to eating. It signals satiety to your brain, slows gastric emptying, and helps regulate blood glucose. GLP-1 receptor agonist medications — semaglutide, tirzepatide, and others — mimic and extend this signal.

The practical effect for patients is simple. Appetite decreases. Food noise — the constant background mental chatter about what to eat next — fades. Portions naturally shrink. Cravings for highly processed foods often soften. For patients with type 2 diabetes, blood glucose control improves alongside.

Tirzepatide goes one step further: it’s a dual GLP-1 / GIP receptor agonist, meaning it activates two metabolic pathways simultaneously. In head-to-head trials, tirzepatide has shown greater average weight loss than semaglutide, though individual response varies and your physician will discuss which medication is appropriate for you.

Who is — and isn’t — a good candidate

GLP-1 therapy is appropriate for adults with obesity, adults with overweight plus weight-related conditions (type 2 diabetes, hypertension, cardiovascular disease, obstructive sleep apnea, or others), and certain patients with type 2 diabetes regardless of weight.

It is not appropriate for everyone. GLP-1 medications are contraindicated in patients with:

• A personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• A history of pancreatitis
• Severe gastrointestinal disease, including gastroparesis
• Pregnancy or active plans for pregnancy

A licensed physician will review your medical history, current medications, and personal risk factors to determine whether GLP-1 therapy is clinically appropriate. This screening is the difference between a real medical program and a service that issues prescriptions based on an intake form alone.

Brand-name vs. compounded: The two paths

In 2026, there are essentially two paths to access GLP-1 medications.

Brand-name FDA-approved medications

semaglutide and tirzepatide are FDA-approved for chronic weight management. oral semaglutide and tirzepatide are FDA-approved for type 2 diabetes. All are manufactured by Novo Nordisk or Eli Lilly. They go through the FDA approval process, follow standardized manufacturing protocols, and have been studied in large clinical trials.

Without insurance coverage, list prices for brand-name GLP-1 medications run roughly $1,000–$1,500 per month. Manufacturer savings cards and direct-to-consumer programs (such as LillyDirect’s vial program) lower the cash-pay cost in some cases. With insurance coverage for weight loss, copays can be modest — but prior authorization, formulary restrictions, and in-network prescriber requirements often make the access path complicated.

Compounded medications from 503A pharmacies

State-licensed 503A compounding pharmacies prepare semaglutide and tirzepatide under state pharmacy board oversight, pursuant to patient-specific prescriptions issued by licensed physicians. These preparations are not FDA-approved as finished drug products. They are dispensed only when a physician determines compounding is clinically appropriate for the individual patient.

Cash-pay compounded programs typically run $200–$500 per month depending on what else is included (labs, coaching, physician follow-up). Compounding allows access without insurance approval, but operates outside the FDA finished-drug-product approval pathway. Patients should ask their physician about the regulatory and clinical differences and make an informed choice.

For a deeper look at the trade-offs, see our guide on how to choose a physician-guided GLP-1 program.

What a real program actually includes

Medication alone is not a program. Patients who treat GLP-1 therapy as just a prescription — fill it, inject it, hope for the best — often see initial weight loss but struggle with sustainability, side effect management, and the protein and muscle preservation work that determines long-term results.

A real physician-guided program includes:

• Ongoing physician oversight. A board-certified physician who reviews your intake, prescribes when clinically appropriate, monitors your response, and adjusts your dose as needed.
• Quarterly metabolic labs. Tracking blood glucose, lipid panel, kidney function, liver function, and thyroid markers — both to verify the medication is working and to catch contraindications or adverse changes early.
• Health coaching. Nutrition guidance focused on adequate protein, nutrient density, and the behavior changes that make results sustainable when you eventually taper or stop.
• Side effect management. A care team you can actually reach when nausea, constipation, or fatigue flare — and a physician who can adjust your titration based on how you’re responding.

The cheapest medication-only services skip most or all of these. They will get you the prescription. They will not get you a program.

The first 90 days

The first three months are the calibration period. Your physician starts you at the lowest dose to let your body adjust, gradually increases your dose according to a standard titration schedule, and reviews your first quarterly labs at the 90-day mark to refine your protocol.

What you’ll experience week-by-week is covered in detail in our guide to the first 90 days on a physician-guided GLP-1 program. The honest short version: appetite changes within days, side effects usually mild and transient, dose increases at weeks 4 and 8, first lab review at week 12.

Real costs, honest numbers

In 2026, the typical cost picture looks like this:

• Brand-name with insurance coverage: $25–$200/month copay, if your plan covers weight loss medications and you meet prior authorization criteria
• Brand-name without insurance, manufacturer savings card: $349–$650/month (LillyDirect vials for tirzepatide, when eligible)
• Brand-name without insurance, retail: $1,000–$1,500/month
• Compounded medication-only services: $150–$300/month (medication only, no labs, no real physician follow-up)
• Compounded full medical program: $200–$500/month (medication, labs, physician, coaching included)

For a deeper look at brand-name tirzepatide pricing specifically, see our complete tirzepatide cost breakdown.

How Elara approaches it

Elara Health and Wellness is a physician-guided GLP-1 program built around the framework above. Every monthly subscription includes compounded semaglutide or tirzepatide from one of our state-licensed 503A pharmacy partners — RedRock Pharmacy, Health Warehouse, Precision Compounding Pharmacy, or Triad Rx — quarterly metabolic labs to track your clinical progress, ongoing access to a licensed clinician for dose adjustments and questions, and dedicated certified health coaches for nutrition and behavior change support. And if you have surgery or another procedure scheduled while on therapy, your program should be able to coordinate disclosure with your surgical team — we cover the protocol in our guide to GLP-1 use before surgery. Single monthly price, no upsells, cancel anytime.

Learn more about Elara’s GLP-1 program or take the 5-minute assessment to see if compounded therapy might be appropriate for you.

Related reading: How to Choose a Physician-Guided GLP-1 Program in 2026: The Complete Guide

---

Compounded semaglutide and tirzepatide are prepared by state-licensed 503A compounding pharmacies under state pharmacy board oversight, pursuant to patient-specific prescriptions issued by licensed clinicians. These medications are not FDA-approved as finished drug products. GLP-1 medications are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Ozempic®, Wegovy® and Rybelsus® are registered trademarks of Novo Nordisk A/S, and Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. Neither company is affiliated with Elara Health and Wellness. Results vary and are not guaranteed. This content is for informational purposes only and is not a substitute for professional medical advice. Consult your physician before starting any treatment.